Roflumilast May Increase Risk of Exacerbations When Used to Treat Poorly Controlled Asthma in People with Obesity.

ABSTRACT: Rationale: People with obesity often have severe, difficult-to-control asthma. There is a need to develop better treatments for this population. One potential treatment is roflumilast, a phosphodiesterase 4 inhibitor, as it is reported to have efficacy for the treatment of asthma and can promote weight loss. Objectives: To investigate the potential efficacy of roflumilast for the treatment of poorly controlled asthma in people with obesity. Methods: A randomized, double-masked, placebo-controlled trial of 24 weeks of roflumilast versus placebo for the treatment of poorly controlled asthma in people with obesity (body mass index of 30 kg/m² or higher). The primary outcome was a change in ACT (Asthma Control Test) score. Results: Twenty-two people were

SUBMITTER: Dixon AE 

PROVIDER: S-EPMC9989863 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature